Journal article
Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy
M Grossmann, EJ Hamilton, C Gilfillan, D Bolton, DL Joon, JD Zajac
Medical Journal of Australia | Published : 2011
Abstract
• Androgen deprivation therapy (ADT) in men with prostate cancer increases the risk of osteoporotic fractures, type 2 diabetes and, possibly, cardiovascular events. • There is considerable uncertainty about the risk-benefit ratio of ADT in non-palliative treatment; the benefits of ADT in treating non-metastatic prostate cancer need to be carefully weighed against the risks of ADT-induced adverse events. • Baseline assessment of bone health at the initiation of ADT should include measurement of bone mineral density (BMD) by dual energy x-ray absorptiometry and, in men with osteopaenia, a thoracolumbar spine x-ray. • General measures to prevent bone loss, including regular physical activity, a..
View full abstractGrants
Funding Acknowledgements
[ "This work was supported by an NHMRC Health Professional Fellowship to Mathis Grossmann, and research grants from Osteoporosis Australia, the Royal Australasian College of Physicians, the Austin Hospital Medical Research Foundation, and the Sir Edward Dunlop Medical Research Foundation.", "Mathis Grossmann is principal researcher of an investigator-initiated trial on the role of bisphosphonates in preventing micro-architectural decay in men with non-metastatic prostate cancer who are receiving androgen deprivation therapy, which is partially supported by Novartis Pharmaceuticals, and has received honoraria for educational lectures from AstraZeneca. Christopher Gilfillan is a member of an AstraZeneca prostate cancer advisory board and has received honoraria for educational lectures from sanofi-aventis and Merck." ]